Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1993 May;92(2):205–210. doi: 10.1111/j.1365-2249.1993.tb03381.x

Failure to detect hepatitis C virus (HCV) genome by polymerase chain reaction in human anti-HCV-positive intravenous immunoglobulins.

F Dammacco 1, D Sansonno 1, A Beardsley 1, E J Gowans 1
PMCID: PMC1554792  PMID: 8387411

Abstract

The prevalence of HCV antibodies was determined by a second-generation ELISA and a four-antigen recombinant immunoblot assay in nine intravenous immunoglobulin (IVIG) preparations commercially available in Italy. In addition, the clinical safety of six of them was ascertained by polymerase chain reaction (PCR) of HCV RNA and a prospective study in 14 patients with immunodeficiency disorders. Results indicated that all IVIG preparations were anti-HCV-positive. However, there were substantial variations in their anti-HCV antibody titres. The preparations retained IgG subclass reactivities to HCV-associated structural (C22-3) and non-structural (C33c, C100-3) proteins. Our sensitive and specific PCR assay was unable to detect HCV RNA in the six preparations tested. Clinical surveillance of IVIG-treated patients prospectively evaluated over a mean period of 8.3 months failed to detect clinical and/or biochemical evidence of hepatitis.

Full text

PDF
205

Images in this article

208Fig. 3
on p.208

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter H. J., Purcell R. H., Shih J. W., Melpolder J. C., Houghton M., Choo Q. L., Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989 Nov 30;321(22):1494–1500. doi: 10.1056/NEJM198911303212202. [DOI] [PubMed] [Google Scholar]
  2. Alter M. J., Margolis H. S., Krawczynski K., Judson F. N., Mares A., Alexander W. J., Hu P. Y., Miller J. K., Gerber M. A., Sampliner R. E. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992 Dec 31;327(27):1899–1905. doi: 10.1056/NEJM199212313272702. [DOI] [PubMed] [Google Scholar]
  3. Barandun S., Castel V., Makula M. F., Morell A., Plan R., Skvaril F. Clinical tolerance and catabolism of plasmin-treated gamma-globulin for intravenous application. Vox Sang. 1975;28(3):157–175. doi: 10.1111/j.1423-0410.1975.tb02755.x. [DOI] [PubMed] [Google Scholar]
  4. Björkander J., Cunningham-Rundles C., Lundin P., Olsson R., Söderström R., Hanson L. A. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med. 1988 Jan;84(1):107–111. doi: 10.1016/0002-9343(88)90016-2. [DOI] [PubMed] [Google Scholar]
  5. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. doi: 10.1126/science.2523562. [DOI] [PubMed] [Google Scholar]
  6. Dodd L. G., McBride J. H., Gitnick G. L., Howanitz P. J., Rodgerson D. O. Prevalence of non-A,non-B hepatitis/hepatitis C virus antibody in human immunoglobulins. Am J Clin Pathol. 1992 Jan;97(1):108–113. doi: 10.1093/ajcp/97.1.108. [DOI] [PubMed] [Google Scholar]
  7. Dodd R. Y. Hepatitis C virus, antibodies, and infectivity. Paradox, pragmatism, and policy. Am J Clin Pathol. 1992 Jan;97(1):4–6. doi: 10.1093/ajcp/97.1.4. [DOI] [PubMed] [Google Scholar]
  8. Han J. H., Shyamala V., Richman K. H., Brauer M. J., Irvine B., Urdea M. S., Tekamp-Olson P., Kuo G., Choo Q. L., Houghton M. Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1711–1715. doi: 10.1073/pnas.88.5.1711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hämäläinen E., Suomela H., Ukkonen P. Virus inactivation during intravenous immunoglobulin production. Vox Sang. 1992;63(1):6–11. doi: 10.1111/j.1423-0410.1992.tb01211.x. [DOI] [PubMed] [Google Scholar]
  10. Imbach P., Perret B. A., Babington R., Kaminski K., Morell A., Heiniger H. J. Safety of intravenous immunoglobulin preparations: a prospective multicenter study to exclude the risk of non-A, non-B hepatitis. Vox Sang. 1991;61(4):240–243. doi: 10.1111/j.1423-0410.1991.tb00953.x. [DOI] [PubMed] [Google Scholar]
  11. Kuo G., Choo Q. L., Alter H. J., Gitnick G. L., Redeker A. G., Purcell R. H., Miyamura T., Dienstag J. L., Alter M. J., Stevens C. E. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989 Apr 21;244(4902):362–364. doi: 10.1126/science.2496467. [DOI] [PubMed] [Google Scholar]
  12. Lever A. M., Webster A. D., Brown D., Thomas H. C. Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet. 1984 Nov 10;2(8411):1062–1064. doi: 10.1016/s0140-6736(84)91506-x. [DOI] [PubMed] [Google Scholar]
  13. Quinti I., Paganelli R., Scala E., Guerra E., Mezzaroma I., D'Offizi G. P., Aiuti F. Hepatitis C virus antibodies in gammaglobulin. Lancet. 1990 Dec 1;336(8727):1377–1377. doi: 10.1016/0140-6736(90)92927-a. [DOI] [PubMed] [Google Scholar]
  14. Römer J., Späth P. J., Skvaril F., Nydegger U. E. Characterization of various immunoglobulin preparations for intravenous application. II. Complement activation and binding to staphylococcus protein A. Vox Sang. 1982 Feb;42(2):74–80. doi: 10.1159/000460851. [DOI] [PubMed] [Google Scholar]
  15. Sansonno D., Dammacco F. Antibodies to hepatitis C virus in non-A, non-B post-transfusion and cryptogenetic chronic liver disease. Lancet. 1989 Sep 30;2(8666):798–799. doi: 10.1016/s0140-6736(89)90855-6. [DOI] [PubMed] [Google Scholar]
  16. Weiland O., Mattsson L., Glaumann H. Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet. 1986 Apr 26;1(8487):976–977. doi: 10.1016/s0140-6736(86)91081-0. [DOI] [PubMed] [Google Scholar]
  17. Weiner A. J., Geysen H. M., Christopherson C., Hall J. E., Mason T. J., Saracco G., Bonino F., Crawford K., Marion C. D., Crawford K. A. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3468–3472. doi: 10.1073/pnas.89.8.3468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Williams P. E., Yap P. L., Gillon J., Crawford R. J., Urbaniak S. J., Galea G. Transmission of non-A, non-B hepatitis by pH4-treated intravenous immunoglobulin. Vox Sang. 1989;57(1):15–18. doi: 10.1111/j.1423-0410.1989.tb04977.x. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES